Uncategorized

Cuidar adecuadamente de nuestra salud bucal es esencial para mantener una sonrisa radiante y prevenir enfermedades dentales. Uno de los pilares fundamentales de la higiene oral es el cepillado dental diario. En este artículo, exploraremos las mejores prácticas respaldadas por la cienci …

Senju Pharmaceutical Co., Ltd. and Novaliq GmbH are pleased to announce the closing of a license agreement on Japan rights to develop, manufacture, and commercialize NOV03, the first and only prescription treatment for signs and symptoms of dry eye disease that directly targets tear evaporation.

BioInvent International Abstract for the ongoing clinical trial with BI-1206 in combination with rituximab has been accepted to the ICML and showcases the study design and status, and summarizes the early clinical results generated so far in the dose escalation phase.

Spago Nanomedical Spago Nanomedical AB announced the establishment of a Scientific Advisory Board comprised of scientific and clinical leaders in oncology and nuclear medicine.

Senju Pharmaceutical Co., Ltd. and Novaliq GmbH are pleased to announce the closing of a license agreement on Japan rights to develop, manufacture, and commercialize NOV03, the first and only prescription treatment for signs and symptoms of dry eye disease that directly targets tear evaporation.

Seagen Inc. announced updated efficacy and safety results from Part C of a phase 2 single-arm trial evaluating the antibody-drug conjugate ADCETRIS® in combination with the PD-1 inhibitor nivolumab and standard chemotherapy agents doxorubicin and dacarbazine for the frontline treatment of patients with early-stage classical Hodgkin lymphoma.

Genezen, a gene and cell therapy contract development and manufacturing organization, announced the appointment of Susan D’Costa, Ph.D. as Chief Technology Officer and Nicole O’Brien, Ph.D. as Chief Commercial Officer.

IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the company will present an abstract at the IBAGS XIV triennial meeting, held on June 13-16, 2023, in Stockholm, Sweden.

Valneva SE, a specialty vaccine company, announces that the Company’s pivotal Phase 3 data for its single-shot chikungunya vaccine candidate, VLA1553, have been published in The Lancet, the world’s leading peer-reviewed medical journal.

Hay varias causas de masas en el cuello, y su diagnóstico diferencial puede ser difícil. El uso de un enfoque sistemático dará como resultado un diagnóstico preciso y la guía para un tratamiento adecuado.